MTF HRT on TikTok: separating real effects from hype

What did @juno_mazzy actually say?

She's been on what she calls "Pajesterone" (progesterone) for about a month and is already noticing appetite changes, some facial fullness she attributes to the hormone, and a worsening of her depression. She's careful to say she's "not blaming that on the Pajesterone" and acknowledges her depression predates HRT. That's actually a more honest framing than most anecdotal HRT content online.

To summarize the specific claims: one month of progesterone increased her appetite after a lifetime of not feeling hungry, she sees fat redistribution in her face, and her antidepressant feels like it's "going out of whack." She flags uncertainty throughout. The credit here is real, she's not overclaiming a dramatic physical transformation after 30 days.

Does the science back this up?

Partly, but the timeline is compressed. Most endocrinologists and the existing literature put meaningful fat redistribution at three to six months minimum, not four weeks. The appetite piece is more defensible.

Progesterone has well-documented effects on appetite regulation. It interacts with hypothalamic pathways that govern hunger signaling, and elevated progesterone levels, whether endogenous or exogenous, are associated with increased caloric intake. This is documented in menstrual cycle research: Dye and Blundell (1997, Physiology and Behavior) found progesterone-dominant luteal phases correlated with increased appetite and food intake compared to follicular phases. So "hungry like a girl" is not just vibes, there's a real mechanism.

The depression piece is messier. Progesterone metabolizes into allopregnanolone, a neurosteroid that modulates GABA-A receptors. For some people this is calming. For others, particularly those with a history of premenstrual dysphoric disorder or treatment-resistant depression, it can worsen mood. Hantsoo and Epperson (2017, Current Psychiatry Reports) documented this individual variability extensively. Her experience is clinically plausible, not a fluke.

What did they get wrong (or right)?

The facial fat claim after one month is almost certainly premature. She's not wrong that progesterone and estrogen together shift fat distribution in transfeminine patients, but a month is not enough time to attribute visible facial changes to hormonal redistribution with any confidence. It could be water retention, weight gain from eating more, or confirmation bias. Give credit for noticing the change, but the mechanism she's implying is probably not what's driving it yet.

What she got right is the antidepressant interaction concern. Progesterone and its metabolites do influence serotonin receptor sensitivity and GABA pathways, and there is legitimate reason to believe this can blunt or alter the effect of SSRIs and SNRIs. This is an underreported issue in transgender care. A 2021 review by Tebbe and Bhatt in the Journal of Clinical Endocrinology noted that mood symptoms during progesterone initiation in transfeminine patients are commonly underaddressed by prescribers. Her read on this is actually clinically sound, even if her phrasing is informal.

Her instinct to ride it out as "a wave" is understandable but not necessarily the right call. Worsening depression during hormone therapy initiation warrants a conversation with her prescriber, not just patience.

What should you actually know?

If you're starting progesterone and you have a pre-existing mood disorder, you should be having an active conversation with whoever manages both your hormones and your psychiatric medications before you start, not after you're already feeling destabilized.

Progesterone's role in transfeminine HRT is still not fully standardized. Unlike estradiol, there are no large randomized controlled trials on progesterone specifically in transfeminine populations. Most of the evidence is extrapolated from cisgender women's health research and small observational studies. The Endocrine Society's 2017 clinical practice guidelines for transgender patients do not include a strong recommendation for or against progesterone in feminizing HRT, specifically because the evidence base is thin.

The appetite effects she describes are biologically real. Increased hunger driven by progesterone is not a placebo. But framing a month of progesterone use as producing visible facial feminization is getting ahead of the biology. The timeline for fat redistribution in feminizing HRT is typically cited as three to six months for initial changes, with full effects taking two to three years (Hembree et al., 2017, Journal of Clinical Endocrinology and Metabolism).

Her antidepressant concern deserves a prescriber visit, not a TikTok comment section. Allopregnanolone, the active progesterone metabolite, is a potent neuroactive steroid. Its interaction with psychiatric medications is real and variable between individuals.